Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

INTRODUCTION: In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer (previously published). Here, we report EGFR mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta, McCormack, Rose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224589/
https://www.ncbi.nlm.nih.gov/pubmed/25122430
http://dx.doi.org/10.1097/JTO.0000000000000263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224589/
https://www.ncbi.nlm.nih.gov/pubmed/25122430
http://dx.doi.org/10.1097/JTO.0000000000000263

Ejemplares similares